Last reviewed · How we verify
Orelabrutinib in combination with rituximab
Orelabrutinib in combination with rituximab is a Small molecule drug developed by The First Affiliated Hospital of Xiamen University. It is currently in Phase 1 development.
At a glance
| Generic name | Orelabrutinib in combination with rituximab |
|---|---|
| Sponsor | The First Affiliated Hospital of Xiamen University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort) (PHASE2)
- Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL (PHASE2)
- Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL) (PHASE2)
- PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. (PHASE2)
- Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma (PHASE4)
- Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma (PHASE2)
- Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment (PHASE2)
- Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Orelabrutinib in combination with rituximab CI brief — competitive landscape report
- Orelabrutinib in combination with rituximab updates RSS · CI watch RSS
- The First Affiliated Hospital of Xiamen University portfolio CI
Frequently asked questions about Orelabrutinib in combination with rituximab
What is Orelabrutinib in combination with rituximab?
Orelabrutinib in combination with rituximab is a Small molecule drug developed by The First Affiliated Hospital of Xiamen University.
Who makes Orelabrutinib in combination with rituximab?
Orelabrutinib in combination with rituximab is developed by The First Affiliated Hospital of Xiamen University (see full The First Affiliated Hospital of Xiamen University pipeline at /company/the-first-affiliated-hospital-of-xiamen-university).
What development phase is Orelabrutinib in combination with rituximab in?
Orelabrutinib in combination with rituximab is in Phase 1.